Published in Oncotarget on March 08, 2016
In vitro exploration of a myeloid-derived suppressor cell line as vehicle for cancer gene therapy. Cancer Gene Ther (2016) 0.78
Dose translation from animal to human studies revisited. FASEB J (2007) 15.67
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61
Immune surveillance of tumors. J Clin Invest (2007) 5.04
Gene therapy progress and prospects: nonviral vectors. Gene Ther (2002) 2.79
VEGF targets the tumour cell. Nat Rev Cancer (2013) 2.71
Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest (2000) 2.70
A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med (2002) 2.55
Cancer immunotherapy--revisited. Nat Rev Drug Discov (2011) 2.26
Gene therapy progress and prospects: electroporation and other physical methods. Gene Ther (2004) 1.55
Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci (2011) 1.24
Canine tumors: a spontaneous animal model of human carcinogenesis. Transl Res (2011) 1.18
Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res (2011) 1.17
Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol (2010) 1.09
Bacteria as vectors for gene therapy of cancer. Bioeng Bugs (2011) 1.05
VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. Eur J Immunol (2010) 1.05
T cell-mediated suppression of angiogenesis results in tumor protective immunity. Blood (2005) 0.99
DNA vaccines against cancer come of age. Curr Opin Immunol (2010) 0.99
Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy. Clin Cancer Res (2007) 0.98
Safety and tolerability of the Easy Vax™ clinical epidermal electroporation system in healthy adults. Mol Ther (2011) 0.92
Expression of vascular endothelial growth factor, basic fibroblast growth factor, and their receptors (flt-1, flk-1, and flg-1) in canine vascular tumors. Vet Pathol (2006) 0.92
A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine (2009) 0.92
CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic. J Gene Med (2012) 0.91
The role of CpG motifs in immunostimulation and gene therapy. Adv Drug Deliv Rev (2000) 0.91
Localization of integrin alpha(v)beta3 and vascular endothelial growth factor receptor-2 (KDR/Flk-1) in cutaneous and oral melanomas of dog. Histol Histopathol (2003) 0.88
Vaccination approach to anti-angiogenic treatment of cancer. Biochim Biophys Acta (2015) 0.88
Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 in canine simple mammary gland adenocarcinomas. Can Vet J (2010) 0.87
Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Vet Immunol Immunopathol (2006) 0.86
Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs. Vaccine (2009) 0.85
Immunity against tumor angiogenesis induced by a fusion vaccine with murine beta-defensin 2 and mFlk-1. Clin Cancer Res (2007) 0.85
Lymphocyte blastogenic responses to cultured allogeneic tumor cells in vitro. Cancer Res (1972) 0.85
Vaccines targeting the neovasculature of tumors. Vasc Cell (2011) 0.84
Taking electroporation-based delivery of DNA vaccination into humans: a generic clinical protocol. Methods Mol Biol (2008) 0.84
A promising new approach of VEGFR2-based DNA vaccine for tumor immunotherapy. Immunol Lett (2009) 0.84
Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication. J Control Release (2014) 0.83
Novel vaccines and adjuvant systems: the utility of animal models for predicting immunogenicity in humans. Hum Vaccin (2010) 0.82
Anti-tumor effects of a human VEGFR-2-based DNA vaccine in mouse models. Genet Vaccines Ther (2009) 0.82
Therapeutic cancer vaccines. Surg Oncol Clin N Am (2007) 0.81
Expression of vascular endothelial growth factor receptor Flk-1 in canine mammary tumours. J Comp Pathol (2004) 0.81
Effect of a novel DNA vaccine on angiogenesis and tumor growth in vivo. Arch Otolaryngol Head Neck Surg (2010) 0.80
Relative potency of cellular and humoral immune responses induced by DNA vaccination. Intervirology (2000) 0.80
Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor in canine cutaneous fibrosarcomas. J Comp Pathol (2009) 0.80
Mannan-modified adenovirus encoding VEGFR-2 as a vaccine to induce anti-tumor immunity. J Cancer Res Clin Oncol (2014) 0.79
Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use? Vaccine (2014) 0.79
Expression of vascular endothelial growth factor and its receptors in canine lymphoma. J Comp Pathol (2007) 0.78
Construction of a DNA vaccine encoding Flk-1 extracellular domain and C3d fusion gene and investigation of its suppressing effect on tumor growth. Cancer Immunol Immunother (2009) 0.78
Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial. Oncoimmunology (2015) 0.77
Superiority of needle-free transdermal plasmid delivery for the induction of antigen-specific IFNgamma T cell responses in the dog. Vaccine (2008) 0.77
Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. J Immunother Cancer (2013) 0.77
Development of novel DNA vaccine for VEGF in murine cancer model. Sci Rep (2013) 0.76
CD8 T-cell induction against vascular endothelial growth factor receptor 2 by Salmonella for vaccination purposes against a murine melanoma. PLoS One (2012) 0.76
Induction of protective and therapeutic antitumor immunity by a DNA vaccine with C3d as a molecular adjuvant. Vaccine (2010) 0.76